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Four hundred sixty-two patients, all with either docu- 
mented spontaneous sustained ventricular tachycardia or 
cardiac arrest unresponsive to other antiarrhythmic drugs 
(2.6/patient), were treated with amiodarone. Thirty-five 
patients (7.6%) failed to respond or died during the initial 
oral or intravenous loading phase. The remaining 427 
patients were discharged on treatment with oral amioda- 
rone and followed up for up to 98 months. Recurrence of 
ventricular tachycardia or sudden cardiac death at 1,3 and 
5 years by life-table analysis was 19%) 33% and 43%, 
respectively, for patients discharged on amiodarone ther- 
apy. The sudden cardiac death rate was 9%, 15% and 
21%, respectively, at 1, 3 and 5 years. 
Amiodarone (Cordarone, Wyeth) is an unusually effective 
antiarrhythmic agent for the prevention of life-threatening 
ventricular arrhythmias (l-lo). Prior reports (11,12) have 
shown marked variation in both efficacy and toxicity. Actu- 
arial studies (13,14) have suggested an overall 1 year mor- 
tality rate of 20% for patients treated with amiodarone for 
ventricular arrhythmias and a 3 year mortality rate of 40%. 
However, many of these studies have included patients with 
complex ventricular ectopic rhythm and nonsustained ven- 
tricular tachycardia rather than sustained ventricular 
arrhythmias. The efficacy of amiodarone in patients treated 
for >3 years has not been reported previously. The inci- 
dence of adverse effects, including those requiring discon- 
tinuation of therapy, has been reported to be very high in 
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Side effects were reported by 45% of patients after 1 
year, by 61% after 2 years and by 86% after 5 years. 
Amiodarone was discontinued because of side effects in 
14%, 26% and 37% of patients after 1, 3 and 5 years, 
respectively. Incidence rates of recurrence of arrhythmia, 
sudden cardiac death and side effects were highest in the 
early months and then decreased. By multivariate analysis, 
advanced age, low ejection fraction and a history of cardiac 
arrest were independent risk factors for sudden cardiac 
death during amiodarone therapy. 
(J Am Co11 Cardiol1989;13:442-9) 
early follow-up studies (13,14), but the appearance of late 
side effects has not been adequately quantitated. 
Long-term data involving large numbers of patients are 
especially important with the advent of newer therapeutic 
modalities including recently released antiarrhythmic 
agents, the automatic implantable cardioverter defibrillator, 
endocardial resection and catheter ablation. In this report, 
we describe our experience with a group of 462 patients with 
a history of sustained ventricular tachycardia or cardiac 
arrest who were treated with amiodarone and followed up 
for up to 98 months; 157 of these patients were treated with 
this drug for >2 years. 
Methods 
Study patients. Between July 1979 and June 1986, 462 
consecutive patients were treated with amiodarone because 
they had documented sustained ventricular tachycardia (du- 
ration >30 s or requiring intervention because of hemody- 
namic collapse) or had been resuscitated from a cardiac 
arrest not associated with acute myocardial infarction. No 
patient was excluded because of underlying cardiac or 
noncardiac disease, congestive heart failure or other indica- 
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Table 1. Characteristics of 427 Patients Discharged 
on Amiodarone 
Age W) 
Gender (male/female) 
Ejection fraction I%~,) 
Age i60 yr 
Age >60 yr 
Prior antiarrhythmic drug failures 
Cardiac diagnosis 
Coronary artery disease 
Prior myocardial infarction 
Dilated cardiomyopathy 
Hypertensive heart disease 
Mitral valve prolapse 
Other valvular heart disease 
Arrhythmogenic right ventricular dysplasia 
Other heart disease 
No structural heart disease 
61 k 12 
341:86 
36 C I4 
31 215 
35 + I3 
2.6 5 I.2 
330 
288 
43 
8 
II 
8 
I4 
IO 
tots of a poor prognosis. Eighty percent of patients were 
male. Seventy percent had coronary artery disease and the 
87% of these had a documented history of myocardial 
infarction; 10% had dilated cardiomyopathy not related to 
coronary artery disease and only 2.3% of patients had no 
demonstrable organic heart disease. All patients had failed to 
respond to one or more conventional or investigational 
agents as assessed either by spontaneous recurrence of the 
arrhythmia or by the persistent inducibility of ventricular 
tachycardia or fibrillation during programmed ventricular 
stimulation. Before the initiation of amiodarone therapy, the 
patients had failed to respond to 2.6 2 1.2 (mean ? SD) other 
antiarrhythmic agents. The clinical characteristics of the 427 
patients discharged from the hospital on amiodarone are 
summarized in Table 1. 
Electrophysiologic studies. After withdrawal of other anti- 
arrhythmic agents and before the initiation of amiodarone, 
342 (74%) of the 462 patients underwent complete elec- 
trophysiologic study including programmed ventricular stim- 
ulation at one or more right ventricular sites with the use of 
up to three ventricular extrastimuli at two drive cycle lengths 
(usually 600 or 500 ms and 400 ms). Details of this protocol 
have been published previously (1.5). A sustained ventricular 
arrhythmia was induced in 261 patients (76% of patients 
undergoing electrophysiologic study). In 40 patients (12%), 
only nonsustained ventricular tachycardia (26 beats) was 
induced, whereas no ventricular tachycardia was induced in 
41 patients (12%). Amiodarone was used in these 40 patients 
without inducible arrhythmia because they had a clear 
history of ventricular tachycardia or ventricular fibrillation 
without any obvious precipitating cause. In 120 patients who 
had frequent episodes of sustained ventricular tachycardia 
or poor overall clinical condition, electrophysiologic study 
was not performed before amiodarone therapy was started. 
In patients with inducible ventricular tachycardia, one or 
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Figure 1. Mean daily amiodarone dose as a function of duration of 
therapy. n = number of patients remaining in follow-up. 
more antiarrhythmic agents were tested with programmed 
stimulation before the start of amiodarone therapy (15). 
Drug loading. After informed consent was obtained and 
with use of a protocol approved by the Human Investiga- 
tions Committee of the University of California, San Fran- 
cisco on February 22, 1979, oral amiodarone therapy (800 
mg/day administered in one or more doses) was initiated in 
295 patients. For 167 patients who had sustained arrhyth- 
mias that were frequent or immediately life threatening or 
who were receiving mechanical ventilation, amiodarone was 
initiated intravenously as an initial loading dose of 5 mg/kg 
body weight followed by a continuous infusion of 1 g/24 h for 
3 days. Patients who continued to have episodes of ventric- 
ular tachycardia or who were unable to take medication 
orally received amiodarone intravenously for up to 7 days 
(16). Patients were monitored continuously for 27 days. 
Long-term therapy. After successful in-hospital amioda- 
rone loading, patients received oral amiodarone, 800 mg/day 
for 4 to 6 weeks, followed by 600 mg/day. During the early 
years of the study, the dose of 600 mg/day was maintained 
unless ventricular tachycardia or fibrillation recurred or 
adverse effects were reported. Because of the high incidence 
of early adverse effects noted (8) it became our policy in 
1983 to decrease the dose to 400 mg/day after 3 to 6 months 
of therapy. However. some patients, at the request of the 
referring physician, continued to receive 600 mg/day. Main- 
tenance doses ranged from 200 mg for 5 of 7 days to 600 mgi 
day. The mean maintenance dose decreased with duration of 
treatment (Fig. I). During the enrollment period (1979 to 
1986) the role of programmed ventricular stimulation in 
predicting efficacy of amiodarone was unclear. Therefore, 
repeat programmed ventricular stimulation was not per- 
formed after the initiation of amiodarone therapy. 
Follow-up. The patients were followed up in the arrhyth- 
mia clinic by one of us or by referring physicians at intervals 
of 3 to 6 months. All patients were interviewed at least every 
6 months when additional drug supplies were requested. 
Blood chemistry determinations, including electrolytes, urea 
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nitrogen, creatinine, liver and thyroid function tests, chest 
radiograph (17), ophthalmologic examination, electrocardio- 
gram (ECG) and 24 h ambulatory (ECG) monitoring were 
performed before initiating amiodarone therapy and approx- 
imately every 6 months. Pulmonary function tests, including 
diffusion capacity of carbon monoxide (18) and gallium 
scanning of the lung (19), were performed at baseline and 
whenever pulmonary toxicity was suspected. 
Efficacy. Efhcacy of amiodarone was assessed by recur- 
rence of symptomatic, sustained ventricular tachycardia or 
fibrillation and sudden cardiac death. Recurrence of arrhyth- 
mia was defined as any documented sustained ventricular 
arrhythmia or sudden cardiac death. Sudden cardiac death 
was defined as naturally occurring instantaneous death, 
unwitnessed death, death occurring during sleep or within 1 
h of onset of symptoms and death occurring as a direct result 
of arrhythmia. This definition allowed the inclusion of pa- 
tients who were resuscitated successfully but ultimately died 
of the consequences of cerebral anoxia or uncontrollable 
arrhythmia. Total deaths included all sudden cardiac deaths 
as well as cardiac and noncardiac nonsudden deaths. Be- 
cause of the long half-life of amiodarone and loading period 
required (1,9), arrhythmia recurrences, sudden cardiac deaths 
and total deaths occurring during the in-hospital loading 
period were analyzed separately. The subsequent analysis of 
the 427 patients includes only those patients who were 
discharged from the hospital alive on amiodarone therapy. 
Arrhythmia recurrences, sudden deaths and total deaths 
were recorded to the nearest 1 month of follow-up. 
Side effects. Cardiac toxicity was defined as worsening of 
arrhythmia or the new onset of symptomatic bradycardia or 
atrioventricular (AV) block. The diagnosis of a proarrhyth- 
mic effect was made when previously undocumented poly- 
morphic ventricular tachycardia or incessant monomorphic 
ventricular tachycardia occurred. In addition, cardiac toxic- 
ity was considered to be present when new, symptomatic 
bradycardia or AV block requiring permanent pacing devel- 
oped 
The diagnosis of amiodarone-induced pulmonary toxicity 
was made when either a new infiltrate appeared on chest 
radiograph (17) and could not be explained by congestive 
heart failure, infection or malignancy or when bronchoscopy 
with biopsy or lavage, pulmonary function studies (18) or 
gallium scanning (19) was consistent with pulmonary toxicity 
in a patient with new symptoms of cough or dyspnea. 
Gastrointestinal toxicity was considered to be present 
when persistent constipation unresponsive to mild laxatives, 
or nausea, vomiting or anorexia occurred at any time after 
the initiation of amiodarone. Asymptomatic elevations of 
serum transaminases were not considered to represent gas- 
trointestinal toxicity and only when clinical hepatitis oc- 
curred was the diagnosis of hepatic toxicity made and 
amiodarone discontinued. 
The diagnosis of neurotoxicity was made when any of the 
following new problems were reported after the initiation of 
amiodarone: tremor, ataxia, muscle weakness, headache, 
paresthesias or sensory or motor neuropathy. Neurologic 
side effects were recorded whether or not they necessitated 
discontinuation of amiodarone. 
Ophthalmic toxicity included only optic neuritis and 
symptomatic cornea1 microdeposits. Asymptomatic cornea1 
microdeposits were followed up with serial eye examinations 
and were neither counted as an adverse drug effect nor 
considered an indication for discontinuation of amiodarone. 
Photosensitivity and skin discoloration were considered 
to represent amiodarone dermatologic toxicity. Minor, 
asymptomatic thyroid function abnormalities were not con- 
sidered to represent amiodarone thyroid toxicity. Only thy- 
roid function abnormalities requiring treatment or discontin- 
uation of amiodarone were counted as adverse drug effects. 
In cases of multiple drug therapy, adverse effects were 
attributed to amiodarone when they persisted after withdraw- 
al of the other agent. When an adverse effect was reported 
and confirmed, it was considered to be present from that point 
onward even if it disappeared with lowering of the dose. 
Statistical methods. Efficacy and incidence of adverse 
effects are presented using life-table analysis (20). Compari- 
sons between two means were made with Student’s t test for 
group observations. Other data are expressed as mean ? SD. 
We examined the relation between five outcome variables 
(sudden death, all deaths, recurrence of arrhythmia, side 
effects and failed treatment defined as either sudden death or 
side effects necessitating discontinuation of drug) and eight 
possible predictor variables (age, gender, ejection fraction, 
presenting arrhythmia, underlying heart disease, number of 
previously unsuccessful antiarrhythmic agents, inducibility 
of a sustained ventricular arrhythmia with programmed 
ventricular stimulation at baseline, drug-free electrophysio- 
logic study and history of prior myocardial infarction). The 
relation between each of the predictors and time to each 
outcome was analyzed with a proportional hazards model 
(21). In this model, the distribution of time to outcome is 
modeled as a hazard function of the predictor variable or 
variables and the outcome. The form of the base hazard 
remains unspecified, minimizing the restrictions placed on 
the parametric form of the underlying time to event distri- 
bution. The model makes full use of censored survival data 
(follow-up times for patients who did not have the event). 
The statistical significance of the proportional hazard coef- 
ficient assesses the significance of the relation between the 
corresponding predictor and outcome. 
Univariate models were generatedfor each of the predic- 
tors with each of the outcomes. In the univariate models, all 
patients with complete data for the particular predictor and 
the particular outcome were included in the analysis. We 
then fit multivariate models, which simultaneously included 
each of the eight predictors, to each of the five outcomes. 
The results from these models indicated the independent 
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contribution of each of the predictors and were simulta- 
neously adjusted for the other predictors in the model. In 
each of the five multivariate models, only patients with 
complete data for all eight predictors and the outcome are 
included in the model. 
One hundred eighty-eight (44%) of the 427 patients were 
deleted from each multivariate model because they were 
missing one or more of the independent predictor variables. 
To check for potential bias in this exclusion, we imputed 
missing data for these three variables and then repeated the 
proportional hazards analyses. For the number of failed 
drugs, each patient with missing data was assigned the overall 
mean value. For the result of electropbysiologic study and 
ejection fraction, a linear model predicting each of these 
variables with use of the complete data for the remaining 
pre ictors was fit to the cases with complete data. The 
& toe cients were then used to calculate predicted values for 
those cases with missing data. This approach produced no 
significant changes in relative risk except as noted in Results. 
Results 
Early failures and cardiac complications. Although amio- 
darone was initiated in 462 patients, only 427 (92%) contin- 
ued on the drug until the time of hospital discharge. An 
early, proarrhythmic effect was seen in seven patients 
(I .5%), four who had received intravenous loading and three 
who had received oral loading. Before entry into the study, 
10 patients (2%) had a permanent pacemaker. Of the remain- 
ing 453 patients, 7 (1.5%) developed early, symptomatic 
bradycardia or AV block and underwent implantation of a 
permanent pacemaker before discharge. Twenty-five pa- 
tients (5.4%) died before hospital discharge and 10 patients 
were discharged on treatment with other antiarrhythmic 
agents or underwent endocardial resection because of early 
drug failure or worsening of arrhythmia. 
Long-term follow-up. During the first month of therapy 
after hospital discharge, 28 patients (7%) had a documented 
recurrence of ventricular tachycardia or ventricular fibrilla- 
tion or sudden cardiac death. The recurrence rate at I. 2, 31 
4 and 5 years was 19%. 26%. 33%, 41% and 43%, respec- 
tively (Fig. 2). By multivariate analysis, left ventricular 
dysfunction and a history of cardiac arrest were independent 
predictors of recurrence (Table 2). After imputing for miss- 
ing data. left ventricular function becomes relatively more 
important and presenting arrhythmia less important. If one 
includes arrhythmia recurrence during the first 7 days of 
drug loading, the incidence rate at 1 month increases to 9%. 
The incidence of sudden cardiac death was also highest 
during the first month after hospital discharge. Thirteen 
patients (3%) died suddenly during the 1st month and by 6 
months, 28 patients (7%) died suddenly. The sudden death 
rate was 9%, 12%, 15%. 21%’ and 21’S, respectively. at I. 1. 
3. 4 and 5 years (Fig. 2). 
SUDDEN AND ARRHYTHMIC DEATHS 
ALL DEATHS 
8 0.2 . . 
g 0.1 . . n-261 n.157 n.lO1 tl.36 n-13 
O= 
0 ‘12 24 36 40 60 
MONTHS IN FOLLOW-UP 
Figure 2. Cumulative proportion of patients free from sudden or 
arrhythmic death, recurrence of sustained ventricular tachycardia or 
fibrillation and all types of death (cardiac and noncardiac, sudden 
and nonsudden). n = number of patients remaining in follow-up. 
Ejection fvaction was quantitated by radionuclide ventri- 
culography, quantitative two-dimensional echocardiography 
or contrast ventriculography before initiation of amiodarone 
therapy in 356 (83%) of the 427 patients. Incidence of sudden 
cardiac death differed significantly when patients with an 
ejection fraction >40% were compared with patients with an 
ejection fraction ~40% (Fig. 3). By multivariate analysis, a 
10% decrease in ejection fraction was associated with a 50% 
increase in sudden death (Table 2). 
Despite similar left ventricular function (ejection fraction 
37 + 15% for patients 560 years of age versus 35 t 13% for 
patients 260 years of age), patients SO years old had a 
higher incidence of sudden cardiac death than did the 
younger patients (Fig. 4). Older patients had a higher inci- 
dence rate of coronary artery disease than did younger 
patients (84% versus 65%, respectively), but a lower inci- 
dence of dilated cardiomyopathy (8% versus 13%. respec- 
tively). A 10 year increment in age was associated with a 
relative risk for sudden death of 2.13 (Table 2). 
Patients presenting with cardiac arrest were 3.14 times as 
likely to experience sudden death as were those who pre- 
sented with sustained ventricular tachycard& Again, imput- 
ing for missing data suggests a greater role fdr left ventricular 
function in predicting outcome. 
Although the occurrence of all deaths (sudden and non- 
sudden, cardiac and noncardiac) was highest during the 1st 
year after discharge (20%) (Fig. 2), the annual mortality 
remained 10% in years 2 through 5. By multivariate analysis, 
older patients, patients with a history of myocardial infarc- 
tion and patients with left ventricular dysfunction were at 
higher risk for death from any cause. Taking into consider- 
ation all 462 patients who were started on amiodarone 
therapy on the basis of intention to treat, the total mortality 
rate was 9% at 1 month, 24% at I year. 43% at 3 years and 
62% at 5 years. Inducibility of ventricular tachycardia in the 
drug-free state, gender and type of underlying heart disease 
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Table 2. Results of Multivariate Analysis in 427 Patients 
Arrhythmia 
Sudden Deaths All Deaths Recurrence Side Effects Failed Therapy* 
Independent Relative Relative Relative Relative Relative 
Variable Hazard p Value Hazard p Value Hazard p Value Hazard p Value Hazard p Value 
Aget 2.13 0.002 1.26 0.03 0.92 NS I.3 0.02 I.51 0.0003 
Gender (male/female) 2.22 NS I.12 NS 1.02 NS I .07 NS 1.33 NS 
Ejection fraction I.54 0.02 1.38 0.001 I.27 0.04 I.15 0.03 0.98 NS 
Presenting 3.14 0.014 1.44 NS 1.82 0.03 1.26 NS 1.45 NS 
arrhythmia$ 
(cardiac arrestNT) 
Heart disease 0.4 NS 0.37 0.06 1.33 NS I.14 NS 0.86 NS 
(CAD/all others) 
No. of failed drugs* 0.77 NS I .69 NS I.16 NS 1.08 NS 0.94 NS 
Inducible VT before 1.33 NS 0.77 NS 1.29 NS I.13 NS 1.23 NS 
amiodarone 
History of MI 1.6 NS 2.46 0.04 I .I4 NS I.13 NS I.15 NS 
*Defined as either occurence of sudden death or side effect requiring discontinuation; trelative hazard associated with a IO yr increase in age; Srelative hazard 
associated with a decrease in ejection fraction of IO percentage points; 8 relative hazard associated with one additional failed drug before amiodarone. CAD = 
coronary artery disease; MI = myocardial infarction; VT = ventricular tachycardia. 
failed to influence survival or side effects in multivariate 
analysis (Table 2). 
Side effects. Amiodarone was always discontinued when 
cardiac or pulmonary toxicity, severe peripheral neuro- 
pathy, clinically significant hepatitis or optic neuritis became 
evident. Other side effects were managed initially with 
reduction in dosage or with drugs aimed at alleviating 
symptoms. Amiodarone was discontinued in 1% of patients 
at 1 month and in 8% of patients at 6 months because of side 
effects. The cumulative incidence of discontinuing amioda- 
rone because of a side effect after 1, 2, 3,4 and 5 years was 
14%, 22%, 26%, 32% and 37%, respectively (Fig. 5). A total 
of 83 patients discontinued amiodarone because of side 
effects. 
During the 1st year of treatment, a total of 172 of the 462 
patients (45% by life-table analysis) reported one or more of 
the adverse drug reactions discussed. The cumulative inci- 
Figure 3. Effect of ejection fraction (EF) on incidence of sudden 
cardiac death. 
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dence of any toxicity at 2,3,4 and 5 years was 54,61,72 and 
86%, respectively (Fig. 5). By multivariate analysis, ad- 
vanced age and left ventricular dysfunction were associated 
with increased likelihood of any side effect. 
Amiodarone was tolerated and prevented recurrence of 
sustained arrhythmia after 1 month in 93% of patients but in 
only 70% of patients after 1 year (Fig. 6). Attrition due to 
arrhythmia recurrence or discontinuation because of a side 
effect was 7.5% per year in years 2 through 5. 
Amiodarone was tolerated and prevented sudden cardiac 
death in 96% of patients after 1 month and in 78% of patients 
after 1 year. Attrition due to sudden cardiac death or 
discontinuation because of a side effect was 7% per year for 
years 2 through 5 (Fig. 6). Patients <60 years old had a 
higher likelihood of continuing on amiodarone without sud- 
den cardiac death at all times during follow-up (Fig. 7). Age 
was the only multivariate predictor of failed therapy. 
Figure 4. Effect of age on cumulative sudden cardiac death 
survival. 
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Figure 5. Cumulative proportion free from any side effect (lower 
curve) and cumulative proportion free from side effects requiring 
discontinuation of amiodarone (upper curve). 
Figure 7. Effect of age on cumulative successful therapy (absence 
of sudden or arrhythmic death or discontinuation because of a side 
effect). 
Cardiac toxicity. Symptomatic bradycardia or AV block 
requiring permanent cardiac pacing was seen in 4 patients at 
5, 8, 11 and 17 months, respectively, after the inpatient 
loading phase. As all patients had either cardiac arrest or 
sustained ventricular tachycardia before beginning amioda- 
rone, proarrhythmia after hospital discharge was difficult to 
identify. Some sudden cardiac deaths, particularly in those 
patients whose initial presentation was stable sustained 
ventricular tachycardia, may have been due to amiodarone- 
induced proarrhythmic effects. 
Pulmonary toxicity. No patient developed pulmonary 
toxicity during the 1st month after hospital discharge. Evi- 
dence for pulmonary toxicity developed in 27 patients (8%) 
during the 1st year. The cumulative incidence rate was 13%, 
15%, 22% and 25% after 2, 3, 4 and 5 years, respectively 
(Fig. 8). A total of 47 patients discontinued amiodarone 
because of pulmonary toxicity during the course of the 
study. All but two of these patients had new infiltrates on 
chest radiography. 
The mean daily dose (mg/day) of the patients who ulti- 
Figure 6. Cumulative success of amiodarone as measured by ab- 
sence of recurrence or discontinuation because of a side effect 
(lower curve) and as measured by absence of sudden or arrhythmic 
death or discontinuation because of a side effect (upper curve). 
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mately developed pulmonary toxicity was 745 ? 107 at 1 
month, 580 t 166 at 6 months. 477 ? 161 at 1 year, 400 -+ 141 
at 2 years and 350 -t 87 at 3 years. These doses did not differ 
significantly from those of patients not experiencing pulmo- 
nary toxicity. 
Pulmonary toxicity was observed more commonly in 
patients 260 years old. The incidence rate at 6 months and 1, 
2,3,4 and 5 years for patients ~60 years of age was I%, 3%, 
7%. 7%, 7% and 20% versus 6%, 11%. 16%, 20%, 25% and 
25%, respectively, for those >60 years of age (p < 0.05 
between 2 and 55 months follow-up). 
Gastrointestinal toxicity. Signs or symptoms of gastroin- 
testinal or hepatic toxicity, excluding asymptomatic trans- 
aminase elevations, developed early during the course of 
amiodarone treatment, with 13 patients (3%) developing 
symptoms during the 1st month after discharge and 9% 
during the 1st year. During years 2 through 5, new gastroin- 
testinal side effects developed at a rate of 2.5% per year (Fig. 
8). Eleven patients discontinued amiodarone because of 
gastrointestinal or hepatic toxicity. 
Neurotoxicity. Neurologic side effects, most commonly 
tremor, were the most frequently observed evidence of 
Figure 8. Cumulative proportion free from gastrointestinal, pulmo- 
nary and neurologic side effects. 
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amiodarone toxicity. During the 1st month after discharge, 
31 patients (7%) complained of neurologic side effects and, 
after 6 months, 73 patients (19%) had developed side effects. 
New onset of neurologic side effects became less frequent 
during the later phases of therapy with an incidence rate of 
4% per year in years 2 through 5 (Fig. 8). During the course 
of the study, 21 patients discontinued amiodarone because of 
intolerable neuromuscular side effects. 
Ophthalmic toxicity. Ophthalmic toxicity developed in 
4% of patients per year over the 5 year course of the study. 
During the course of the study, 11 patients discontinued 
amiodarone because of ophthalmic side effects. 
Dermatologic toxicity. Unlike all other side effects to 
amiodarone, the annual incidence of dermatologic side ef- 
fects increased with longer exposure to amiodarone. During 
the first 2 years of therapy, annual incidence was 3.3%, while 
during the subsequent 3 years, annual incidence was 17%. 
However, only three patients discontinued amiodarone be- 
cause of dermatologic toxicity. 
Thyroid toxicity. Hyper- and hypothyroidism were the 
least commonly observed side effects of amiodarone therapy 
with a 5 year cumulative incidence of only 18%. Only two 
patients discontinued amiodarone because of thyroid toxic- 
ity. 
Discussion 
Efficacy. The efficacy of amiodarone for patients with 
sustained ventricular tachycardia or fibrillation is difficult to 
assess from published reports (3-9,13,14,22). In many previ- 
ous studies (3,4,6,7,9,13,14), patients with nonsustained ven- 
tricular tachycardia have been included. Some patients with 
nonsustained ventricular tachycardia have an excellent prog- 
nosis regardless of treatment and this factor may significantly 
bias the results of uncontrolled studies (23). The present study 
comprises the largest group of patients, with the longest 
follow-up, yet reported. The population is homogeneous in 
that all patients had sustained ventricular tachycardia or 
cardiac arrest. In addition, multivariate clinical predictors of 
outcome are presented for the first time. Early, smaller 
studies (4-6,8) with follow-up of 1 to 3 years have demon- 
strated successful therapy in 50% to 80% of patients at 1 year. 
Using life-table analysis, we found a 93% likelihood of suc- 
cess at 1 month and an 80% likelihood of success at 6 months. 
Like many of the previous studies that reported a mean 
follow-up of about 1 year, the rate of success defined as 
arrhythmia control without toxicity, was 70% at 1 year in our 
study. Despite the 30% failure rate during the 1st year, failure 
rates in the subsequent 4 years averaged only 7.5% per year. 
Recurrences. Arrhythmia tended to recur early in treat- 
ment, perhaps, in part, because of inadequate drug loading. 
Amiodarone levels were not available during the early 
phases of the study and were not used as a guide to therapy 
at any time during the study. Seven percent of patients had 
a recurrence during the 1st month and nearly half of these 
recurrences were fatal. By the end of 2 months’ therapy, 9% 
of patients had had a recurrence and 4% had died suddenly. 
Sudden cardiac death. The same pattern of early failure 
was observed for the occurrence of sudden cardiac death. 
The incidence rate of sudden cardiac death was 9% in the 1st 
year but only 3% per year for subsequent years. This 
incidence rate is similar to that reported by Swerdlow et al. 
(24) for patients whose drug, surgical or device therapy was 
predicted by electrophysiologic study to be successful. 
Recent studies (25-27) have documented the importance 
of ventricular tachycardia induction studies in patients 
treated with amiodarone. Because of the high 1 and 2 month 
arrhythmia recurrence and sudden cardiac death rates, such 
studies probably should be performed before hospital dis- 
charge. 
Side effects. As in previous studies (11-15) side effects 
were observed frequently and necessitated the discontinua- 
tion of amiodarone therapy in 14% of patients during the 1st 
year. However, for subsequent years, the annual incidence 
rate of discontinuation of amiodarone therapy because of 
side effects decreased to 6%, a rate substantially lower than 
that reported by Smith et al. (14) who noted intolerable side 
effects in 70% of patients by 5 years. These differences may 
be related at least in part to differences in patient population. 
The patients studied by Smith et al. were being treated 
predominantly for supraventricular tachycardia. All patients 
in our study had a history of sustained ventricular arrhyth- 
mias and, therefore, may have been more likely to continue 
treatment in the face of mild side effects. On multivariate 
analysis, advanced age and lower ejection fraction indepen- 
dently predicted the development of side effects. 
Pulmonary toxicity. The most serious potential side effect 
of amiodarone is pulmonary toxicity (17,28-30). From prior 
studies, its incidence over time is unclear and varies from 
1.4% of 432 patients (28) to 15.1% of 77 patients (30). In the 
cooperative study of 1,307 patients reported by Mason et al. 
(13) the 1 year incidence rate was 14% and the 3 year 
incidence rate was 28%. In the present study, the 1st year 
incidence rate was 8%, but the overall incidence rate was 5% 
per year over the 5 year follow-up. Despite the trend to 
lower doses with time, pulmonary toxicity continued to 
appear at similar rates over long-term follow-up. Older 
patients were significantly more likely to develop pulmonary 
toxicity than were younger individuals. 
Early onset of neurologic toxicity was very common early 
during therapy. With decreasing dosage, new complaints of 
neurologic side effects decreased to 4% per year in years 2 
through 5. However, late neurologic side effects were fre- 
quently manageable only by discontinuing amiodarone. 
Gastrointestinal, ophthalmic and thyroid toxicity were 
rarely seen despite the long exposure to the drug. Because 
dermatologic side effects tend to appear only after >2 years 
of therapy, these have been underestimated in previous 
reports. 
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Clinical implications. Amiodarone can be used safely and 
successfully in approximately half of patients treated for 5 
years. Of particular importance is the relatively low inci- 
dence of sudden or arrhythmic death (approximately 3% per 
year) after the 1st year. This incidence compared favorably 
with the reported (31) incidence of this complication after 
insertion of an automatic defibrillator. Although the inci- 
dence of significant toxic effects increases with continued 
exposure to the drug, it decreases sharply after the 1st year. 
Therefore, there would appear to be little rationale for 
arbitrarily switching to more aggressive nonpharmacologic 
interventions for patients who have been successfully 
treated with amiodarone for >I year. 
Because of the higher incidence of subsequent sudden 
death in patients with cardiac arrest treated with amioda- 
rone, the automatic implantable cardioverter-defibrillator 
should be considered early in the course of these patients. 
The recent study of Fogoros et al. (32) suggests improved 
survival in patients with syncope and ventricular tachycardia 
treated with the automatic implantable cardioverter defibril- 
lator and amiodarone compared with that in patients treated 
with amiodarone alone. The poorer outcome of older pa- 
tients and those with poor left ventricular function may not 
be unique to amiodarone. 
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